查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445542

血管生成抑制剂和促进剂市场评估：按产品、应用、最终用户和地区划分的机会和预测（2017-2031）

Angiogenesis Inhibitors and Stimulators Market Assessment, By Product, By Application, By End-user By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 231 Pages | 商品交期: 3-5个工作天内

价格

2024-2031年预测期内，全球血管生成抑制剂和促进剂市场规模将以10.01%的复合年增长率增长，从2023年的251.5亿美元增长到2031年的539亿美元，预计将增长至5000万美元。

各种类型的癌症（包括肺癌、乳癌和摄护腺癌）的负担日益增加，导致对治疗方法开发的投资增加。 据美国癌症协会称，2023 年仅美国就将报告 1,958,310 例新癌症病例和 609,820 例癌症相关死亡。 此外，人们对使用血管生成抑制剂和促进剂治疗各种疾病的认识的提高和技术的进步也支持了市场的成长。 技术进步正在彻底改变血管生成抑制剂和促进剂的开发。 新的药物传输系统，包括脂质体和奈米颗粒，正在减少副作用并提高药物疗效。 此外，组织工程技术和生物材料的整合正在支持调节血管生成新方法的开发。

癌症盛行率的增加支持市场成长

世界各地各种类型癌症的盛行率不断增加，增加了对血管生成抑制剂的需求。 这些抑制剂透过抑制新血管的形成来阻止肿瘤生长并稳定肿瘤。 根据约翰霍普金斯大学医学发表的论文，血管生成抑制剂贝伐单抗已被证明可有效治疗多种类型的癌症，包括转移性肾细胞癌、大肠直肠癌、神经内分泌肿瘤、非小细胞肺癌、胶质母细胞瘤和肝癌癌症。它可用于癌症治疗。

重视研发活动

研发活动有许多好处，包括支持创新、促进新产品和服务的开发以及提高现有产品的有效性。 这些活动提高了标靶治疗的准确性和有效性，并使研究人员能够减少其产品现有的限制。 各个参与公司和研究机构都致力于研发活动，以加速治疗有效产品的开发，并了解现有治疗方法与其他治疗方法相结合的有效性。 武田药品工业株式会社发起了一项干预措施，旨在评估鲁沙佐米联合地塞米松和来那度胺对先前接受硼替佐米诱导治疗的患者在2 年内对多发性骨髓瘤进展的影响。该试验的第4 期试验目前正在进行中。 本研究正在调查接受地塞米松和来那度胺合併鲁沙佐米全口服合併治疗的参与者的安全性和有效性。

本报告调查了全球血管生成抑制剂和促进剂市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构和市场成长。影响因素分析、案例研究、竞争优势分析主要公司的概况和概况。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球血管新生抑制剂与促进剂市场展望

  • 市场规模/预测
  • 按产品
    • 血管新生管形成测定
    • 微流控
    • 内皮黏附
    • 侵袭和迁移测定
  • 依用途
    • 体外血管生成
    • 体内血管生成
  • 最终用户
    • 医院
    • 诊所
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第 5 章全球血管新生抑制剂与促进剂市场展望：按地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 按产品
  • 依用途
  • 按最终用户
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 生长抑制因素（问题、限制因素）

第 9 章监理架构与创新

  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Pfizer, Inc.
  • Novartis AG
  • Abbott Laboratories
  • F. Hoffmann-La Roche, Ltd.
  • Johns Hopkins Medicine
  • Bristol-Myers Squibb Company
  • Eyetech, Inc.
  • Bayer AG
  • Takeda Pharmaceutical Company Ltd.
  • Sun Pharmaceutical Industries Ltd.

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX11091

Global angiogenesis inhibitors and stimulators market is projected to witness a CAGR of 10.01% during the forecast period 2024-2031, growing from USD 25.15 billion in 2023 to USD 53.95 billion in 2031. The growing burden of different types of cancers, including lung, breast, and prostate cancer, is increasing investments in developing different therapeutic treatments. As per the American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths occurred in the United States alone. Furthermore, the growing awareness about the utilization of angiogenesis inhibitors and stimulators for the treatment of various conditions and technological advancements are supporting the market growth. Advancements in technology are revolutionizing the development of angiogenesis stimulators and inhibitors. Novel drug delivery systems, including liposomes and nanoparticles, reduce side effects and improve drug efficacy. Additionally, tissue engineering techniques and the integration of biomaterials are supporting the development of novel avenues for modulation of angiogenesis.

The growth of medical tourism in different regions across the globe is also expected to augment the growth of the market in the coming years. Such factors encourage different governments and research organizations to support novel product development and research activities. Key players and market and research institutions are heavily engaged in research and development activities to develop novel products that offer enhanced therapeutic efficacy. For instance, the National Cancer Institute of Naples are in the phase 4 of a study that is being conducted to explore the role of biological and clinical factors in patients with ovarian cancer who are receiving paclitaxel and carboplatin with bevacizumab.

Increasing Prevalence of Cancer Supports Market Growth

The growing prevalence of different types of cancer in various regions across the globe is propelling the requirement for angiogenesis inhibitors. These inhibitors prevent the growth of the tumor and stabilize it by blocking the formation of new blood vessels. According to an article published by Johns Hopkins Medicine, Bevacizumab, an angiogenesis inhibitor medicine, aids in the treatment of different types of cancer, including metastatic renal cell cancer, colorectal cancer, neuroendocrine tumors, non-small cell lung cancer, glioblastoma, and liver carcinoma.

Due to the central role of the VEGF/VEGFR signaling axis in cancer angiogenesis, various anti-angiogenic medicines, including VEGFR tyrosine kinase inhibitors (TKIs), anti-VEGF antibodies, and anti-VEGFR antibodies, have been authorized for different types of cancer. Researchers Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. discovered that treatment with Bevacizumab and hypoxia-inducible factor 1(HIF-1) inhibitors have a greater anti-cancer impact as opposed to therapy with Bevacizumab only in glioma xenografts. Furthermore, various market players are also investing in evaluating the safety and efficacy of Bevacizumab, including Hoffmann-La Roche, which is conducting a stage four clinical trial in an interventional study of Bevacizumab in patients suffering from metastatic or advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Increasing Emphasis on Research and Development Activities

Research and development activities offer various benefits, including supporting innovation, facilitating the development of novel products and services, and enhancing the efficacy of existing products. These activities enhance the accuracy and efficacy of targeted therapies and allow researchers to reduce the existing limitations of the product. Various market players and research organizations are heavily engaged in research and development activities to promote the development of products that provide enhanced therapeutic efficacy and understand the effects of existing therapies in combination with others. For instance, Takeda Pharmaceuticals is in phase 4 of their interventional study that aims to evaluate the effect of lxazomib in combination with dexamethasone and lenalidomide on the progression of multiple myeloma in two years in patients who had previously received a bortezomib-based induction regimen. The study will look at the safety and effectiveness of participants who are taking the all-oral combination of dexamethasone and lenalidomide with lxazomib.

North America Dominates Angiogenesis Inhibitors and Stimulators Market

North America is expected to account for a significant share of the market owing to the strong presence of various leading market players and the rapid expansion of the biotechnology and pharmaceutical industry in the region. The large patient base and expansion of the treatment seeking population in North America are further bolstering the market growth.

Due to the increasing prevalence of various diseases, including diabetic retinopathy, metastasis, and tumor formulation, various research institutions and organizations are heavily investing in research activities for the development of novel therapies and enhancing their efficacy. For instance, the Greater Houston Retina Research is in the phase four of their interventional study of long-term efficacy and safety of intravitreal aflibercept injections for treating diabetic retinopathy for subjects who completed the 2-year PANORAMA trial. The subjects will be evaluated for efficacy with the aid of best corrected visual acuity by using spectral domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), optical coherence tomography angiography (OCT-A), FP, 4-meter ETDRS protocol with normal-luminance, and Humphrey Visual Field (HVF) through 112 weeks.

In Vitro Angiogenesis Accounts for Significant Market Share

The in vitro application accounts for a significant share of the market owing to the increasing utilization of the device for the measurement of proteins among other substances available in tissues and biological fluids, such as serum, blood, and urine. For instance, the CHEMICON In Vitro Angiogenesis Kit provides a system for evaluating tube formation by endothelial cells in a 96-well format. This kit represents a simple model of angiogenesis where the inhibition or induction of tube formation by exogenous signals is monitored easily. The assay can be used for monitoring the extent of tube assembly in different endothelial cells such as bovine capillary endothelial cells and human umbilical vein cells.

Hospitals Expected to Witness Significant Growth Over Forecast Period

The hospital segment is expected to generate significant revenue due to the high demand for angiogenesis inhibitors and stimulators owing to increased awareness and rising incidences of patients with uncontrolled angiogenesis. The increased spending of hospitals on angiogenesis inhibitor and stimulator therapies can also be attributed to the growing requirement for innovative therapies due to the expansion of the medical tourism industry. The increasing prevalence of age-related macular degeneration is further encouraging hospitals to invest in angiogenesis inhibitors as they are critical for the treatment and prevention of the disease. According to an article published in Journal Cureus, in September 2022, it was estimated that 200 million people suffer from AMD. This number is projected to increase to roughly 300 million by 2040.

Future Market Scenario (2024 - 2031F)

Takeda Pharmaceuticals, one of the leading research and development driven pharmaceutical companies, is involved in an interventional study that aims to evaluate the effect of lxazomib in combination with dexamethasone and lenalidomide on the progression of multiple myeloma in two years in patients who had previously received a bortezomib-based induction regimen. The study is expected to conclude in November 2026.

The National Cancer Institute of Naples is in the phase 4 of a study that is being conducted to explore the role of biological and clinical factors in patients with ovarian cancer that are receiving paclitaxel and carboplatin with bevacizumab. The study is expected to conclude in December 2024.

Key Players Landscape and Outlook

Key participants in the angiogenesis inhibitors and stimulators market include F. Hoffmann-La Roche, Ltd., Bristol-Myers Squibb Company, Eyetech, Inc., Bayer AG, and Takeda Pharmaceutical Company Ltd. The market is witnessing significant growth owing to rising investments in healthcare infrastructure, advancements in precision medicine, and increasing prevalence of cancer.

Hoffmann-La Roche, a multinational healthcare and pharmaceutical company, is conducting a stage four clinical trial in an interventional study of Bevacizumab in patients suffering from metastatic or advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The study is expected to conclude in June 2025.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Angiogenesis Inhibitors and Stimulators Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Angiogenesis Tube Formation Assays
    • 4.2.2. Microfluidic
    • 4.2.3. Endothelial Adhesion
    • 4.2.4. Invasion and Migration Assays
  • 4.3. By Application
    • 4.3.1. In Vitro Angiogenesis
    • 4.3.2. In Vivo Angiogenesis
  • 4.4. End-user
    • 4.4.1. Hospitals
    • 4.4.2. Clinics
    • 4.4.3. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. South America
    • 4.5.3. Europe
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East & Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Angiogenesis Inhibitors and Stimulators Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Angiogenesis Tube Formation Assays
      • 5.1.2.2. Microfluidic
      • 5.1.2.3. Endothelial Adhesion
      • 5.1.2.4. Invasion and Migration Assays
    • 5.1.3. By Application
      • 5.1.3.1. In Vitro Angiogenesis
      • 5.1.3.2. In Vivo Angiogenesis
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Clinics
      • 5.1.4.3. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Product
      • 5.1.5.2.1. Angiogenesis Tube Formation Assays
      • 5.1.5.2.2. Microfluidic
      • 5.1.5.2.3. Endothelial Adhesion
      • 5.1.5.2.4. Invasion and Migration Assays
      • 5.1.5.3. By Application
      • 5.1.5.3.1. In Vitro Angiogenesis
      • 5.1.5.3.2. In Vivo Angiogenesis
      • 5.1.5.4. End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Clinics
      • 5.1.5.4.3. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Application
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. Abbott Laboratories
  • 13.4. F. Hoffmann-La Roche, Ltd.
  • 13.5. Johns Hopkins Medicine
  • 13.6. Bristol-Myers Squibb Company
  • 13.7. Eyetech, Inc.
  • 13.8. Bayer AG
  • 13.9. Takeda Pharmaceutical Company Ltd.
  • 13.10. Sun Pharmaceutical Industries Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 10. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 11. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 16. United States Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 17. United States Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 21. Canada Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 22. Canada Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 26. Mexico Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 27. Mexico Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 31. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 32. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 37. Germany Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 38. Germany Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 42. France Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 43. France Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 47. Italy Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 48. Italy Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 52. United Kingdom Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 53. United Kingdom Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 57. Russia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 58. Russia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 62. Netherlands Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 63. Netherlands Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 67. Spain Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 68. Spain Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 72. Turkey Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 73. Turkey Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 77. Poland Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 78. Poland Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 82. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 83. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 88. Brazil Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 89. Brazil Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 93. Argentina Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 94. Argentina Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 98. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 99. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 101. India Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 104. India Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 105. India Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 109. China Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 110. China Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 114. Japan Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 115. Japan Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 119. Australia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 120. Australia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 124. Vietnam Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 125. Vietnam Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 129. South Korea Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 130. South Korea Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 134. Indonesia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 135. Indonesia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 139. Philippines Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 140. Philippines Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 144. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 145. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 150. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 151. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 155. UAE Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 156. UAE Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 160. South Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 161. South Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023